New oral anticoagulants to revolutionise venous thromboembolism (VTE) management

References 

1. Autar. R., 2002. Advancing Clinical Practice in the Management of Deep Vein Thrombosis (DVT). The Autar DVT Scale Revalidated. PhD thesis. DeMontfort University, Leicester.
2. Autar R. The management of deep vein thrombosis: the Autar DVT risk assessment scale revisited. Journal of Orthopaedic Nursing. 2003;7:114–124
3. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition. 2008;36(2):386–399
4. Boris LC. New compounds in the management of venous thromboembolism after orthopaedic surgery: focus on rivaroxaban. Vascular Health Risk Management. 2008;4(4):855–862
5. Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. Journal of Thrombosis and Haemostasis. 2003;1:2119–2130
6. De Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. New England Journal of Medicine. 2005;353(26):2827–2834
7. Douketis JD, Elkeboom JW, Quinland DJ, et al. Short duration prophylaxis against venous thromboembolism after total hip and knee arthroplasty: a meta-analysis of prospective studies investigating symptomatic outcomes. Archive of Internal Medicine. 2003;162:1465–1471
   • MEDLINE
   • CrossRef
8. Eriksson BL, Lassen MR. The PENTasaccharide in Hip FRActure surgery plus (PENTHIFRA plus) investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture: a multicentre randomized, placebo-controlled double study. Archive of Internal Medicine. 2003;163:1337–1342
   • MEDLINE
   • CrossRef
9. Eriksson BL, Dahl OE, Kurth AA, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis. 2007;5:2178–2185
10. Eriksson BL, Dahl OE, Rosencher N, et al. Dabigatran etexilate compared with enoxaparin for the extended prevention of venous thromboembolism following total hip replacement. Lancet. 2007;370:949–956
    • Abstract
    • Full Text
    • Full-Text PDF (129 KB)
    • CrossRef
11. Eriksson BL, Borris LC, Friedman RI, et al. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty. New England Journal of Medicine. 2008;358:2765–2775
12. Freedman KB, Brookenthal KR, Fitzerald RH, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. Journal of Bone and Joint Surgery. 2001;82:928–938
13. Friedman RJ, Caprini JA, Comp PC, et al. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee replacement. Journal of Thrombosis and Haemostasis. 2007;5(Suppl. 2):OC051
14. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. American Journal of Health System Pharmacy. 2008;65(16):1520–1529
15. Hass S. Managing the risk of venous thromboembolism in orthopaedics: concluding remarks. Orthopaedics. 1999;(Suppl.):2627
16. Hirsh J. Oral anticoagulant drugs. New England Journal of Medicine. 1991;324:1865–1875
17. Hirsh J, O’Donnell M, Eikelboom JW. Beyond Unfractionated heparin and warfarin: current and future advances. Circulation. 2007;216:552–560
18. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short term enopxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet. 2008;372:31–39
    • Abstract
    • Full Text
    • Full-Text PDF (174 KB)
    • CrossRef
19. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. New England Journal of Medicine. 2008;358:2776–2786
20. Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, direct factor Xa inhibitor. Seminar in Thrombosis and Hemostasis. 2007;33(5):515–523
    • CrossRef
21. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery. Clinical Pharmacokinetics. 2008;47(3):203–216
    • CrossRef
22. NICE, 2007. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in surgical inpatients. National Institute for Clinical Excellence.
23. NICE . Final appraisal determination- dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. National Institute for Health and Clinical Excellence. 2008;2008(July):1–24
24. NICE, 2009. Rivaroxaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 170. National Institute for Health and Clinical Excellence, London, pp. 1–22.
25. Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie. 2007;4:282–289
26. Scurr JH. How long after surgery does risk of thromboembolism persists?. Acta Chirurgica Scandinavica. 1990;556(Suppl.):22–24
27. Shargel L, Yu AB. Applied Biopharmaceutics. fourth ed.. New York: McGraw-Hill; 1999;
28. Turpie AGG. Oral direct factor Xa Inhibitors in development for the prevention and treatment of thromboembolic diseases. Arteriosclerosis, Thrombosis and Vascular Biology. 2007;27:1238–1247
29. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thrombosis Haemostasis. 2003;90(3):446–455